Darifenacin treatment of patients ≥ 65 years with overactive bladder: Results of a randomized, controlled, 12-week trial

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2347-2358

  Chapple, Christopher ^a,d   DuBeau, C ^b   Ebinger, U ^c   Rekeda, L ^c   Viegas, A ^c  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CHICAGO   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Antimuscarinic; Clinical trial; Darifenacin; Elderly; Overactive bladder

Indexed keywords

DARIFENACIN; ENALAPRIL; INDAPAMIDE; ISOSORBIDE DINITRATE; LACIDIPINE; PLACEBO; POTASSIUM CHLORIDE; QUINAPRIL; SIMVASTATIN; VINPOCETINE;

AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY COLIC; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERACTIVE BLADDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; XEROSTOMIA;

AGED; BENZOFURANS; DOUBLE-BLIND METHOD; HUMANS; MUSCARINIC ANTAGONISTS; PLACEBOS; PYRROLIDINES; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 35648994890     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007X226294     Document Type: Article

References (27)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
3. Andersson K-E. Pharmacological treatment of urinary incontinence. In: Incontinence, 2nd international consultation of incontinence Plymouth: Plymbridge Distributors Ltd; 2002. p. 479-511
4. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001;19:299-306
5. 3 receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001;21:243-8
6. 3 receptor selectivity. Eur Urol 2002;1:23-8
7. Tinetti ME, Bogardus ST, Agostini JV. Potential pitfalls of disease specific guidelines for patients with multiple conditions. New Engl J Med 2004;351:2870-4
8. Ouslander JG. Geriatric considerations in the diagnosis and management of overactive bladder. Urology 2002;60:50-5
9. Andersson K-E, Kahler K, Ebinger U. Prevalence of cardiovascular co-morbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract]. https://wwwicsoffice org/publications/2007/PDF/0342PDF [last accessed 7 June 2007]
10. Andersson K-E, Kahler K, Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract]. https://www.icsoffice. org/publications/2007/PDF/0437.PDF [last accessed 7 June 2007]
11. Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. Br Med J 2006;332:455-9
12. Nitti VW. Clinical impact of overactive bladder. Rev Urol 2002;4:S2-S6
13. 3 selective receptor antagonist. Eur Urol 2005;48:471-7
14. Chapple CR. Darifenacin is effective in improving the major symptoms of overactive bladder: a pooled analysis of phase III studies [abstract]. Eur Urol Suppl 2004;3:130
15. Hill S, Elhilali M, Millard R, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. [in press]
16. DuBeau CE. The aging lower urinary tract. J Urol 2006;175:S11-S15
17. Dmochowski RR, Sanders SW, Appell RA, et al. Bladder-health diaries: an assessment of 3-day vs 7-day entries. Br J Urol Int 2005;96:1049-54
18. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. Br J Urol Int 2005;95:580-6
19. Noether G. Sample size determination for some common nonparametric tests. J Am Stat Assoc 1987;82:645-7
20. Desu MM, Raghavarao D. Nonparametric statistical methods for complete and censored data. Boca Raton: Chapman and Hall/CRC; 2003
21. Malone-Lee JG, Walsh JB, Maugourd M-F, et al. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
22. Zorzitto ML, Holliday PJ, Jewett MAS, et al. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 1989;18:195-200
23. Szonyi G, Collas Dm, Ding YY et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287-91
24. van Leeuwen JH, Castro R, Busse M, et al. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006;50:440-52
25. DuBeau CE, Khullar V, Versi E. 'Unblinding' in randomized controlled drug trials for urinary incontinence: implications for assessing outcomes when adverse effects are evident. Neurourol Urodyn 2005;24:13-20
26. Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
27. Coyne K, Matza LS. Validation of the perception of bladder condition measure in overactive bladder [abstract]. http://www.icsoffice.org/publications/ 2002/pdf/231.pdf [last accessed 19 June 2007]